Last week, Professor Brook Baker filed an Amicus Brief responding to four of the arguments made by Pfizer against the compulsory license requested by KEI in the Dominican Republic to allow the distribution of the generic version of Paxlovid. His… Continue Reading
On March 18, 2022, Pfizer filed a 45 page opposition to the KEI application for a compulsory license on Paxlovid patents in the Dominican Republican. This is the Pfizer filing, and KEI’s unofficial translation. Pfizer-opposition-DR-CL-18March2022.pdf Translation-Pfizer-opposition-KEI-CL-Paxlovid-18march2022.pdf The December 3, 2021… Continue Reading
Published in an article by Sydney Lupkin of NPR, the Pfizer-US government contract for the COVID-19 therapeutic Paxlovid contains terms of interest in broader drug pricing discussions. The Pfizer contract includes a “Most Favored Nation Clause” (H.7), which provides that… Continue Reading
On Friday, December 3, 2021, KEI requested an open public interest license to allow the exploitation of PF-07321332 (marketed in combination with ritonavir under the brand Paxlovid) in the Dominican Republic. PF-07321332, being developed by Pfizer, has shown promising results… Continue Reading